BioCryst Pharmaceuticals Inc

BCRX Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of BCRX by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Purchase $1,001 - $15,000 Oct 16, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Sep 15, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Aug 11, 2022
BCRX Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
BCRX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BCRX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in BCRX holdings by institutional investors

Insider Trading

Quarterly net insider trading by BCRX's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $10,000 Oct 22, 2018 Issue: None
  • $20,000 Jul 20, 2018 Issue: None
  • $20,000 Jul 20, 2018 Issue: None
  • $20,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 22, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 22, 2018 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Apr 20, 2017 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Apr 20, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 23, 2017 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jan 23, 2017 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Oct 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Sep 26, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2016 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jul 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Apr 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Oct 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Oct 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $40,000 Jul 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $20,000 Jul 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Apr 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Apr 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $40,000 Jan 20, 2015 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jan 20, 2015 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Oct 20, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Oct 20, 2014 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $40,000 Jul 21, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $20,000 Jul 21, 2014 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies
  • $10,000 Apr 21, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $10,000 Apr 21, 2014 Issue: Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs
  • $10,000 Apr 07, 2014 Issue: Medical/Disease Research/Clinical Labs Defense Health Issues Homeland Security
  • $40,000 Oct 21, 2013 Issue: Pharmacy Defense Disaster Planning/Emergencies Medical/Disease Research/Clinical Labs Health Issues
  • $20,000 Oct 21, 2013 Issue: Medical/Disease Research/Clinical Labs Pharmacy Health Issues Disaster Planning/Emergencies Defense
  • $40,000 Jul 22, 2013 Issue: Health Issues Disaster Planning/Emergencies Pharmacy Medical/Disease Research/Clinical Labs Defense
  • $20,000 Jul 22, 2013 Issue: Medical/Disease Research/Clinical Labs Pharmacy Health Issues Disaster Planning/Emergencies Defense
  • $30,000 Jul 18, 2013 Issue: Homeland Security Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs Science/Technology Defense
  • $30,000 Oct 20, 2011 Issue: Health Issues
  • $20,000 Oct 17, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Jul 20, 2011 Issue: Health Issues
  • $30,000 Jul 20, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Apr 20, 2011 Issue: Health Issues
  • $30,000 Apr 12, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Jan 20, 2011 Issue: Health Issues
  • $30,000 Jan 18, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Jan 18, 2011 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Oct 20, 2010 Issue: Health Issues
  • $50,000 Oct 14, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Oct 14, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Jul 20, 2010 Issue: Health Issues
  • $30,000 Jul 19, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jul 12, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $50,000 Apr 20, 2010 Issue: Health Issues
  • $50,000 Apr 19, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Apr 12, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jan 20, 2010 Issue: Health Issues
  • $30,000 Jan 14, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jan 13, 2010 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Oct 13, 2009 Issue: Health Issues
  • $30,000 Oct 13, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jul 10, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Apr 16, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $30,000 Jan 13, 2009 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Oct 17, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Jul 16, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $20,000 Apr 17, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Feb 05, 2008 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Aug 13, 2007 Issue: Homeland Security Economics/Economic Development
  • $40,000 Feb 13, 2007 Issue: Homeland Security
  • $40,000 Jul 27, 2006 Issue: Medical/Disease Research/Clinical Labs Homeland Security
  • $40,000 Feb 14, 2006 Issue: Medical/Disease Research/Clinical Labs Homeland Security
  • $40,000 Jul 29, 2005 Issue: Homeland Security Medical/Disease Research/Clinical Labs
Corporate Lobbying

BCRX Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

BCRX Revenue by Segment or Geography

By Segment
By Geography
BCRX Income Statement
BCRX Balance Sheet
BCRX Cash Flow
U.S. Patents

New BCRX patent grants

  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Jul. 01, 2025
  • Patent Title: Human plasma kallikrein inhibitors Dec. 10, 2024
  • Patent Title: Antiviral treatments Oct. 22, 2024
  • Patent Title: Human plasma kallikrein inhibitors Oct. 15, 2024
  • Patent Title: Imidazole-containing inhibitors of alk2 kinase Aug. 06, 2024
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jul. 23, 2024
  • Patent Title: Methods and compositions for treatment of zika virus infection May. 07, 2024
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jan. 09, 2024
  • Patent Title: Human plasma kallikrein inhibitors Nov. 07, 2023
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jul. 25, 2023
  • Patent Title: Human plasma kallikrein inhibitors Jul. 25, 2023
  • Patent Title: Human plasma kallikrein inhibitors Jul. 25, 2023
  • Patent Title: Human plasma kallikrein inhibitors Jun. 27, 2023
  • Patent Title: Imidazole-containing inhibitors of alk2 kinase May. 30, 2023
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Apr. 04, 2023
  • Patent Title: Prodrugs of kallikrein inhibitors Apr. 04, 2023
  • Patent Title: Indole compounds and analogues thereof Jan. 24, 2023
  • Patent Title: Antiviral treatments Oct. 11, 2022
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jun. 28, 2022
  • Patent Title: Human plasma kallikrein inhibitors Jan. 25, 2022
  • Patent Title: Human plasma kallikrein inhibitors Dec. 21, 2021
  • Patent Title: Human plasma kallikrein inhibitors Dec. 07, 2021
  • Patent Title: Methods and compositions for inhibition of polymerase Nov. 16, 2021
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor Sep. 14, 2021
  • Patent Title: Methods of treating hematologic cancers Sep. 07, 2021
  • Patent Title: Human plasma kallikrein inhibitors Jul. 20, 2021
  • Patent Title: Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors Jun. 01, 2021
  • Patent Title: Methods and compositions for treatment of zika virus infection Mar. 02, 2021
  • Patent Title: Compositions and uses of amidine derivatives Feb. 02, 2021
  • Patent Title: Benzopyrazole compounds and analogues thereof Dec. 01, 2020
  • Patent Title: Prodrugs of kallikrein inhibitors Sep. 01, 2020
  • Patent Title: Human plasma kallikrein inhibitors Jun. 23, 2020
  • Patent Title: Crystalline salts of a plasma kallikrein inhibitor May. 26, 2020
  • Patent Title: Human plasma kallikrein inhibitors Feb. 18, 2020
  • Patent Title: Methods and compositions for treatment of zika virus infection Dec. 24, 2019
  • Patent Title: Methods and compositions for inhibition of polymerase Sep. 24, 2019
  • Patent Title: Antiviral treatments Aug. 27, 2019
  • Patent Title: Human plasma kallikrein inhibitors Jun. 25, 2019
  • Patent Title: Human plasma kallikrein inhibitors Nov. 13, 2018
  • Patent Title: Antiviral treatments Sep. 26, 2017
  • Patent Title: Compositions and methods for inhibiting viral polymerase Feb. 28, 2017
  • Patent Title: Anti-influenza compositions and methods Nov. 22, 2016
  • Patent Title: Methods and compositions for inhibition of polymerase Nov. 15, 2016
  • Patent Title: Antiviral treatments Jul. 15, 2014
  • Patent Title: Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-d] pyrimidin-4-one Aug. 06, 2013
  • Patent Title: Antiviral nucleoside analogs May. 14, 2013
  • Patent Title: Tetrahydrofuro [3,4-d] dioxolane compounds for use in the treatment of viral infections and cancer Aug. 14, 2012
  • Patent Title: Hepatitis c therapies Apr. 24, 2012
  • Patent Title: Therapeutic furopyrimidines and thienopyrimidines Mar. 13, 2012
  • Patent Title: Antiviral therapeutic agents Aug. 09, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to BCRX from public contracts

BCRX News

Recent insights relating to BCRX

CNBC Recommendations

Recent picks made for BCRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BCRX

BCRX Analyst Ratings

BCRX Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
BCRX Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $BCRX stock a Buy, Sell, or Hold?

  • What is the price target for $BCRX stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

BCRX Top Shareholders
Shareholder
Shares Held
BCRX Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $BCRX stock?

  • Who owns the most shares of $BCRX stock?

  • What funds own $BCRX stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BCRX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BCRX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About BCRX

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

  • Address Durham, NC
  • Market Cap 1.5 billion
  • Employees 580
  • Industrial Classification Biological Products, (No Disgnostic Substances)
Back To Top